Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Fda crawled date : 2022 - 12 - 22 save search
Owlet Announces FDA Software-as-a-Medical Device Submission for Heart Rate and Oxygen Displays and Notifications
Published: 2022-12-22 (Crawled : 23:00) - biospace.com/
OWLT | $3.86 -1.28% 0.0% 8.1K
|
|
| O: -1.32%
H: 6.63%
C: -3.84%
fda device heart oxygen submission
Neurocrine Biosciences Announces U.S. FDA Accepts Supplemental New Drug Application for Valbenazine as a Treatment for Chorea Associated with Huntington Disease
Published: 2022-12-22 (Crawled : 22:00) - biospace.com/
NBIX M | $132.03 -0.39% -0.39% 560K
|
Health Technology
|
| O: 0.46%
H: 1.52%
C: 1.25%
huntington treatment fda drug disease application huntington’s disease
Sunlenca® (lenacapavir) Receives FDA Approval as a First-in-Class, Twice-Yearly Treatment Option for People Living With Multi-Drug Resistant HIV
Published: 2022-12-22 (Crawled : 18:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.03%
H: 0.26%
C: 0.04%
sunlenca treatment fda hiv approval living
Akebia Therapeutics Received Interim Response to Appeal for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease from the FDA
Published: 2022-12-22 (Crawled : 14:00) - prnewswire.com
AKBA | $1.36 -2.16% -2.21% 2.9M
|
Health Technology
|
| O: -1.27%
H: 10.95%
C: 1.33%
treatment fda disease kidney anemia therapeutics response
Aquestive Therapeutics Announces Completion of FDA End-of-Phase 2 Meeting For AQST-109 (epinephrine sublingual film)
Published: 2022-12-22 (Crawled : 13:20) - aquestive.com
AQST | $4.11 -8.67% -9.49% 2.3M
|
Health Technology
|
| O: -0.38%
H: 5.5%
C: 0.22%
aqst-109 fda meeting therapeutics phase 2
Rocket Pharmaceuticals Provides Update on Anticipated Registration Path for RP-A501 in Danon Disease Following End-of-Phase 1 FDA Meeting
Published: 2022-12-22 (Crawled : 12:20) - biospace.com/
RCKT M | $22.82 -2.81% -2.89% 960K
|
Health Technology
|
| O: -9.24%
H: 1.19%
C: -5.14%
fda pharmaceuticals disease meeting update rp-a501 danon disease phase 1
Everest Medicines' Licensing Partner Pfizer Announces FDA and EMA Acceptance of Etrasimod Regulatory Submissions for Ulcerative Colitis Everest Medicines announced that its licensing partner, Pfizer In...
Published: 2022-12-22 (Crawled : 12:00) - biospace.com/
CYDY | $0.1509 0.06% 810K
|
Manufacturing
|
| O: -4.34%
H: 0.35%
C: -5.13%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.48%
H: 0.56%
C: 0.45%
fda ema ulcerative colitis
Everest Medicines' Licensing Partner Pfizer Announces FDA and EMA Acceptance of Etrasimod Regulatory Submissions for Ulcerative Colitis Everest Medicines announced that its licensing partner, Pfizer Inc. has received acceptance from the U.S. Food and Drug Administration for review a New Drug Application for etrasimod for individuals living with moderately-to-severely active ulcerative colitis.
Published: 2022-12-22 (Crawled : 07:00) - biospace.com/
CYDY | $0.1509 0.06% 810K
|
Manufacturing
|
| O: -4.34%
H: 0.35%
C: -5.13%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.48%
H: 0.56%
C: 0.45%
fda drug active ema application review food living ulcerative colitis
Everest Medicines' Licensing Partner Pfizer Announces FDA and EMA Acceptance of Etrasimod Regulatory Submissions for Ulcerative Colitis
Published: 2022-12-22 (Crawled : 01:00) - prnewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.48%
H: 0.56%
C: 0.45%
fda ema ulcerative colitis
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.